Figure 6.

Inhibition of proplatelet formation by megakaryocytes from a patient with congenital, severe P2Y₁₂ deficiency. The effects of the indicated P2Y inhibitors and of apyrase on proplatelet formation by megakaryocytes from a patient with congenital severe P2Y₁₂ deficiency were tested under the same experimental conditions as those used for normal megakaryocytes. Means±SD, n=4 separate experiments, except for apyrase (n=1). *P<0.05 compared to untreated control (CTRL) and MRS 2179 treated samples (ANOVA and Bonferroni's t-test as a post-hoc test).